Experience Leucine AI.
Powered Pharma Operations

Transform Your Pharma Operations with AI-Powered Intelligence. Experience how Leucine's integrated platform brings together manufacturing, quality, and laboratory operations in one digital ecosystem. Schedule a personalized demo to see how our AI solutions can optimize your processes, ensure compliance, and drive operational excellence.

See How AI Transforms Your Shop Floor Operations.
Experience firsthand how Leucine's 10x MES digitalizes batch records, streamlines production, and provides real-time monitoring of your manufacturing operations. Schedule a personalized demo to discover how our AI-powered platform can enhance your productivity while maintaining compliance.

Experience AI-Driven Quality Management in Action.
See how Leucine's 10x QMS automates compliance workflows, streamlines change control, and ensures regulatory adherence. Schedule a demo to learn how our AI-powered platform can help you manage quality processes more efficiently while reducing compliance risks.

Discover Smart Laboratory Operations Management.
Watch how Leucine's 10x LES orchestrates your lab operations, automates documentation, and ensures data integrity. Schedule a demo to see how our AI-powered platform can accelerate your testing processes while maintaining audit-readiness.

Optimize your manufacturing processes with paperless operations
Strengthen quality management and regulatory compliance
Accelerate laboratory operations and testing workflows

Connect with a Leucine Expert

Schedule a 30-Minute Product Demo with Expert Q&A

Sub System
Computer System Validation

Computer System Validation

View Detailed Analysis

Analytics Overview

13
Form 483s Issued
1
483s converted to WL
13
Total Observation
Form 483s Issued
+74 from last period

Analytics Overview

Form 483 Conversion Rate by Year
Form 483s Issued (Yearly)

Recent Form 483s & Warning Letters

View all 483’s
Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
23 Apr 2024
Zydus Lifesciences Limited
Drugs
01 Mar 2024
Amphastar Pharmaceuticals, Inc.
Drugs
16 Jan 2024
Jiangsu Hengrui Pharmaceuticals Co., Ltd
Drugs
22 Dec 2023
Eugia US Manufacturing LLC
Drugs
10 Feb 2023
AGC Biologics Inc.
Drugs

Top Investigators

Investigator Name
Form 483 Count
Warning Letter Count
Arsen Karapetyan
3
0
Camerson E Moore
2
0
Yasamin Ameri
2
0
Andrew 'Drew' Haack, PhD
1
0
Brian Janelsins, PhD
1
0
TITLE/ COMPANY Issue Date Status Details
Appropriate controls are not exercised over computers or related systems
Zydus Lifesciences Limited
23 Apr 2024 Normal Justification: The validation process ensures that computer systems operate correctly and produce accurate, reliable output. This observation points to deficiencies in the system’s validation regarding data integrity and operational reliability.
Excerpt: The software is not configured with an autosave function, allowing analysts to make changes to entry before manually saving without committing the changes to the audit trail.
View Details
Computer systems are not maintained within an appropriate state.
Amphastar Pharmaceuticals, Inc.
01 Mar 2024 Normal Justification: The failure to validate spreadsheets directly impacts the reliability and accuracy of test results and product quality.
Excerpt: Excel spreadsheets used to perform assay and impurity calculations were not validated to ensure accuracy of the test results obtained.
View Details
Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.
Jiangsu Hengrui Pharmaceuticals Co., Ltd
16 Jan 2024 Normal Justification: The compliance of computerized systems to 21 CFR part 11 is crucial in maintaining data integrity and ensuring that only authorized personnel can make changes.
Excerpt: Your firm's GMP related computerized systems and equipment spread across manufacturing workshops are not 21 CFR part 11 compliant.
View Details
Input to and output from the computer and records or data are not checked for accuracy
Eugia US Manufacturing LLC
22 Dec 2023 Normal Justification: The issues related to unexpected data appearance indicate deficiencies in the validation of the NetSCADA system.
Excerpt: It is unclear how this data were acquired in this system and whether or not there are controls in place to avoid the addition or deletion of data.
View Details
Your firm has not established adequate procedural controls to protect the electronic data acquisition and manufacturing control systems used for DS manufacturing in Building at the AGC Biologics Bothell facility.
AGC Biologics Inc.
10 Feb 2023 Normal Justification: Computer system validation is crucial for ensuring systems operate as intended and data integrity is maintained.
Excerpt: The computerized system used to control and collect process data from a SoloVPE and other systems have not been validated.
View Details

Prepare Better for FDA Audits with FDA Tracker

Get Real-time Insights: FDA 483s & Warning letters.
Uncover Trends: FDA Investigator profiles & Observations.
Stay Compliant: Manage risks proactively.